

ASX ANNOUNCEMENT
5 November 2008

Austin Health Comes on Board BNC105 Trial

Key Points

- **Clinical sites engaged in current trial expands to four**
- **Ensures patient enrolment on track**

5 November 2008; Adelaide, Australia: Bionomics Limited (ASX:BNO), today announced that a fourth clinical centre, Austin Health based in Melbourne, has been initiated. Austin Health will participate in the final stage of the ongoing clinical trial of anti-cancer drug BNC105.

The trial is being conducted under an IND approved by the US Food and Drug Administration (FDA) and in January this year, Cancer Trials Australia (CTA) and Bionomics entered an agreement to conduct a first time in human study with Bionomics' anti-cancer drug BNC105.

Austin Health joins other clinical sites within the CTA network at the Royal Melbourne Hospital, the Peter MacCallum Cancer Centre and the Western Hospital.

Dr. Deborah Rathjen, CEO and Managing Director of Bionomics commented: "The current BNC105 clinical trial is progressing well through the dose escalation phase, with BNC105 demonstrating preliminary indications of biological effect as determined by DCE-MRI and CT scans. As the trial progresses towards its conclusion there will be a requirement to recruit greater numbers of patients to confirm the dose to be selected for Phase II trials. It is important that this recruitment proceed as smoothly as possible and it is very pleasing to see Austin Health now part of the team to ensure that happens. CTA members are very experienced in early phase clinical trials and the oncologists involved represent some of the very best in the field."

Dr Geoffrey Chong, lead investigator for the trial at Austin Health said " We are very pleased to open the trial at Austin Health and for our patients to have access to this interesting new agent."

BNC105 is a new type of anti-cancer drug called a Vascular Disruption Agent (VDA) which blocks the blood supply to a solid tumour, effectively "starving" the tumour of nutrients.

VDAs (Vascular Disruption Agents) have significant clinical potential in the treatment of cancer, as they may potentially be applied across a very wide variety of cancer types, including colon, lung and breast cancers. The market potential for VDAs has been estimated at approximately US\$5 billion annually (ASInsights, 2003)

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

Media Enquiries

Therese Minehan
Buchan Consulting
+612 9237 2800 / 0414 388 955
tminehan@bcg.com.au

About Bionomics Limited

Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' most advanced program, BNC105 for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.

For more information about Bionomics, visit www.bionomics.com.au

About Cancer Trials Australia (CTA)

CTA is a Clinical Trial Network and Site Service Organisation providing research governance, advisory and laboratory assay services to investigators and sponsors of clinical trials in the field of oncology. Its member's organisations are:

Austin Health
Bendigo Health
Border Medical Oncology
Ludwig Institute for Cancer Research
Melbourne Health
Peninsula Oncology Centre
Peter MacCallum Cancer Centre
Southern Health
St Vincents Health
The Walter and Elisa Hall Institute
Western Hospital

For further information on CTA please contact:

Mr Marcus Clark, Chief Executive Officer CTA - 03 9342 7306.
Chief Executive Officer
Cancer Trials Australia
6 East, Main Block
The Royal Melbourne Hospital
Grattan Street
Parkville Victoria 3050
+61 (0) 3 9342 7306

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of BNC105, BNC210, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the

requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.